Evidence map›Paper›PMID 9245782›Full record

ArticleThe Journal of cell biology1997

ADP ribosylation factor 1 is required for synaptic vesicle budding in PC12 cells.

V Faúndez, J T Horng, R B Kelly

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of cell biology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 98 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. CaThe Journal of biological chemistry · 2017
    Article
  5. Review
  6. Review
  7. Article
  8. Multiple dileucine-like motifs direct VGLUT1 trafficking.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Loss of AP-3 function affects spontaneous and evoked release at hippocampal mossy fiber synapses.Proceedings of the National Academy of Sciences of the United States of America · 2006
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

V FaúndezDepartment of Biochemistry and Biophysics, The Hormone Research Institute, University of California, San Francisco, California 94143-0534, USA.
J T Horng
R B Kelly
University of California, San Francisco · US

Funding

The Presynaptic Vesicle Cycle for the Slow Acting Neurotransmitter SecretionP01DA010154 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KREITZER, ANATOL, SULZER, DAVID · 1995 to 2016
$14.7M
ANTIBODIES TO SYNAPTIC VESICLESR01NS015927 · NINDS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI KELLY, REGIS B · 1985 to 2005
$1.5M
BIOCHEMISTRY OF SYNAPTIC TRANSMISSIONR01NS009878 · NINDS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI KELLY, REGIS B · 1985 to 2001
$574k
NIDA NIH HHS DA10154NIDA NIH HHS P01 DA010154NINDS NIH HHS NS09878NINDS NIH HHS NS15927NINDS NIH HHS R01 NS015927
6 · The paper itself

Abstract

Carrier vesicle generation from donor membranes typically progresses through a GTP-dependent recruitment of coats to membranes. Here we explore the role of ADP ribosylation factor (ARF) 1, one of the GTP-binding proteins that recruit coats, in the production of neuroendocrine synaptic vesicles (SVs) from PC12 cell membranes. Brefeldin A (BFA) strongly and reversibly inhibited SV formation in vivo in three different PC12 cell lines expressing vesicle-associated membrane protein-T Antigen derivatives. Other membrane traffic events remained unaffected by the drug, and the BFA effects were not mimicked by drugs known to interfere with formation of other classes of vesicles. The involvement of ARF proteins in the budding of SVs was addressed in a cell-free reconstitution system (Desnos, C., L. Clift-O'Grady, and R.B. Kelly. 1995. J. Cell Biol. 130:1041-1049). A peptide spanning the effector domain of human ARF1 (2-17) and recombinant ARF1 mutated in its GTPase activity, both inhibited the formation of SVs of the correct size. During in vitro incubation in the presence of the mutant ARFs, the labeled precursor membranes acquired different densities, suggesting that the two ARF mutations block at different biosynthetic steps. Cell-free SV formation in the presence of a high molecular weight, ARF-depleted fraction from brain cytosol was significantly enhanced by the addition of recombinant myristoylated native ARF1. Thus, the generation of SVs from PC12 cell membranes requires ARF and uses its GTPase activity, probably to regulate coating phenomena.

Indexed as

MacrolidesADP-Ribosylation Factor 1ADP-Ribosylation FactorsAnimalsAnti-Bacterial AgentsAntigens, Viral, TumorBrefeldin ACell-Free SystemCell MembraneCyclopentanesEndocytosisEndosomesEnzyme InhibitorsGTP-Binding ProteinsHumansMembrane ProteinsADP-Ribosylation Factor 1ADP-Ribosylation FactorsAnti-Bacterial AgentsAntigens, Viral, Tumorbafilomycin A1Brefeldin ACyclopentanesEnzyme InhibitorsGTP-Binding ProteinsillimaquinoneMacrolidesMembrane ProteinsQuinonesRecombinant ProteinsR-SNARE ProteinsTransferrin

Identifiers

PMID9245782
PMCPMC2141633
OpenAlexW2119123632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.